The short answer
A triple agonist is a single molecule that activates three distinct receptors. That differs from combination therapy, where separate agents are given together. One molecule means one pharmacokinetic profile, one manufacturing process and one fixed activity ratio.
Key facts
- Definition
- One molecule, three receptors
- Example
- Retatrutide (GIPR, GLP-1R, GCGR)
- Dual agonist example
- Tirzepatide (GIPR, GLP-1R)
- Contrast
- CagriSema (two molecules combined)
- Advantage
- One PK profile; fixed ratio
- Limitation
- Ratio cannot be adjusted
Single molecule versus combination
Two ways to engage several targets. Give several drugs, as CagriSema does with cagrilintide and semaglutide in one injection. Or engineer one molecule that does all of it, as retatrutide does. Both are combination pharmacology; only the second is a multi-agonist.
What one molecule buys
A single pharmacokinetic profile. With separate agents, each has its own absorption, distribution and clearance, and matching them is a real formulation problem. One reason CJC-1295 is usually paired with a short-acting partner rather than its long-acting form. A single molecule cannot fall out of step with itself.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What it costs
Flexibility. The activity ratio is fixed at the design stage and cannot be adjusted afterwards. If a different balance turns out to be preferable, that requires a new molecule rather than a dose change. A combination of separate agents can be re-proportioned; a multi-agonist cannot.
Why multi-agonists are hard to design
Every substitution affects affinity at all targets simultaneously. Improving one usually costs another, so the design space is heavily constrained. This is why multi-agonists exist only within receptor families, GIP, GLP-1 and glucagon receptors are related enough for one scaffold to work,and why no small molecule has achieved it.
Where the field stands
GLP-1 alone, then dual with GIP as tirzepatide, then triple with glucagon as retatrutide. Each step up has produced larger reported reductions and higher gastrointestinal burden. Whether a quadruple agonist is feasible or useful is an open question; the design difficulty compounds with each receptor added.
Quick reference
| Receptors | Molecules | |
|---|---|---|
| Semaglutide | GLP-1 | One |
| Tirzepatide | GIP + GLP-1 | One |
| Retatrutide | GIP + GLP-1 + glucagon | One |
| CagriSema | Amylin + GLP-1 | Two combined |
Frequently asked questions
- Is a triple agonist the same as combination therapy?
- No. A triple agonist is one molecule activating three receptors; combination therapy gives separate agents together.
- What is the advantage of one molecule?
- A single pharmacokinetic profile. Separate agents have to be matched for absorption and clearance, which is a real formulation problem.
- What is the disadvantage?
- The activity ratio is fixed at design. Changing it requires a new molecule rather than a dose adjustment.
Extended research context
The Retatrutide Research deep dive
Deep dive: how the triple-agonist scaffold was engineered
Retatrutide's 39-residue backbone was designed by Eli Lilly's peptide chemistry team to preserve the pharmacophores of three glucagon-family receptors on a single chain. The N-terminal domain retains GIP-receptor contacts, mid-chain substitutions restore GLP-1-receptor affinity lost in native GIP, and additional residue swaps confer glucagon-receptor engagement. A γGlu-2xOEG linker anchors a C20 fatty diacid at Lys17, which reversibly binds serum albumin and slows renal clearance. This is the same albumin-tethering strategy Novo Nordisk pioneered with semaglutide and Lilly refined further in tirzepatide.
The TRIUMPH Phase 3 programme in context
TRIUMPH is Lilly's global Phase 3 development umbrella for retatrutide, spanning obesity (TRIUMPH-1 through TRIUMPH-4), type 2 diabetes, MASH (metabolic dysfunction-associated steatohepatitis), and knee osteoarthritis linked to obesity. Readouts began in 2025 and continue through 2026. Because the compound is investigational, no regulator (FDA, EMA, or MHRA) has issued marketing authorisation, and legitimate supply exists only for laboratory reference and research contexts, never for human administration.
How retatrutide differs from tirzepatide and semaglutide at the mechanism level
Semaglutide is a mono-agonist (GLP-1 only). Tirzepatide is a dual agonist (GIP + GLP-1). Retatrutide adds glucagon-receptor activity, which pre-clinical and Phase 2 data suggest contributes to energy expenditure in addition to appetite regulation and glucose-dependent insulin release. This three-receptor combination is why retatrutide is sometimes called a 'metabolic multi-tool' peptide in the trade press, but the pharmacology is more nuanced than the label implies.
Research applications
- ▸In vitro receptor-binding assays across GIP-R, GLP-1R and GCGR panels
- ▸Comparator studies alongside semaglutide, tirzepatide and liraglutide reference standards
- ▸Analytical-method development: HPLC retention profiling and LC-MS confirmation
- ▸Stability testing of lipidated 39-residue peptides in aqueous and lyophilised forms
- ▸Reference material for teaching incretin pharmacology in university-level courses
Handling checklist
- ✓Store lyophilised vials at −20 °C; protect from light and humidity
- ✓Reconstitute with bacteriostatic water; avoid vortexing (foams the peptide)
- ✓Once reconstituted, store at 2–8 °C and use within 28 days
- ✓Verify batch CoA: HPLC ≥98%, mass matches ~4,731 Da, endotoxin low
- ✓Do not administer to humans or animals. Research use only
Common research-handling mistakes
Learnt from thousands of researcher orders across our UK labs.
✗ Confusing retatrutide with tirzepatide in supplier catalogues
Fix: Cross-check the LY code (LY3437943 = retatrutide; LY3298176 = tirzepatide) and the receptor profile on the CoA.
✗ Using tap or filtered water for reconstitution
Fix: Only use bacteriostatic water for injection (0.9% benzyl alcohol) or sterile water, never lab DI water.
✗ Storing reconstituted solution at room temperature
Fix: Refrigerate at 2–8 °C immediately after reconstitution; discard after 28 days.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Related questions researchers ask
- Is retatrutide the same molecule as LY3437943?
- What is the correct spelling: retatrutide or retatrutid?
- Is retatrutide a GLP-1 drug?
- Which company makes retatrutide?
- When will retatrutide be FDA approved?
- Is retatrutide legal in the UK?
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- PubMedCoskun T et al. Cell Metab 2022 (PMID 35985340)pubmed.ncbi.nlm.nih.gov
- PubMedJastreboff AM et al. NEJM 2023 (PMID 37366315)pubmed.ncbi.nlm.nih.gov
- PubMedSURMOUNT-1: Tirzepatide once weekly for obesity. NEJM 2022 (PMID 35658024)pubmed.ncbi.nlm.nih.gov
- TrialClinicalTrials.gov · TRIUMPH-1 (NCT05929066). Retatrutide Phase 3 obesity trialclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-2 (NCT05929079). Retatrutide in type 2 diabetesclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-3 (NCT05882045). Retatrutide + established CVDclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-4 (NCT05931367). Retatrutide once weeklyclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-5 (NCT06662383). Retatrutide vs tirzepatideclinicaltrials.gov
- TrialClinicalTrials.gov · TRIUMPH-6 (NCT06859268). Maintenance of weight reductionclinicaltrials.gov
- PubMedRosenstock J et al., Retatrutide for people with type 2 diabetes. Lancet 2023 (PMID 37385280)pubmed.ncbi.nlm.nih.gov
- DrugBankDrugBank · Retatrutide (DB18435)go.drugbank.com
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Written and reviewed by
The UK Peptides Editorial Team · Research library, UK Peptides
The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.
More Retatrutide Research articles
- Retatrutide: Spellings, Codes and What Each FindsRetatrutide, LY3437943, reta. Which term finds the science, which finds the market, and the two Lilly codes easily confused with it.
- The History of RetatrutideFrom the 2022 Cell Metabolism discovery paper through Phase 2 in NEJM to the TRIUMPH Phase 3 readouts of 2026 and a signalled FDA filing.
- Retatrutide Clinical Trial Timeline: Phase 1 to TRIUMPHRetatrutide trial timeline: Phase 1 in 2020, Phase 2 in NEJM 2023, Phase 3 TRIUMPH readouts December 2025 to July 2026, FDA filing signalled for Q1 2027.
- Who Develops Retatrutide?Eli Lilly, under the code LY3437943. Why that matters for reading trial data, and why no licensed retatrutide product exists.
- Retatrutide Half-Life: Where It Comes FromThe C20 diacid binds albumin reversibly, supporting once-weekly trial dosing. Why chain length sets duration across the whole incretin family.
Popular across the research hub
One flagship guide from every other research category.
- GHK-Cu (Copper Peptide)GHK-Cu and Collagen Synthesis Research
- TB-500 (Thymosin β4 fragment)How Thymosin Beta-4 Was Discovered
- BPC-157 (Pentadecapeptide)Why BPC-157 and TB-500 Are Called the Wolverine Stack
- CJC-1295 & IpamorelinModified GRF (1-29): What the Name Means
- Peptide ReferenceLyophilisation: Why Peptides Arrive as Powder
- Bacteriostatic WaterWhat Is BAC Water? The Abbreviation Explained
- Research & Regulatory NewsWhat the Cardiovascular and Kidney Data Actually Is
- GLP-1 & Incretin ScienceThe Endpoint Changes When the Patient Is Still Growing
- MOTS-c (Mitochondrial Peptide)MOTS-c and Exercise: What the Published Research Shows
- Semax (ACTH Fragment Peptide)Semax in the Published Literature
- Selank (Tuftsin Analogue)Selank Structure, Sequence and Physical Properties
- DSIP (Delta Sleep-Inducing Peptide)The Missing Biology: No Gene, No Precursor, No Receptor
- KLOW (Blend)What You Can and Cannot Ask a Four-Component Blend
- GLOW (Blend)Why a Blend Must Be Verified Before It Is Blended
- MT-2 (Melanotan II)MT-2 Chemical Identity and the Database Trap
- IGF-1 LR3Recombinant Versus Synthetic: Two Different Quality Problems
- GlutathioneGSH and GSSG: What the Ratio Measures
- NAD+The Membrane Problem: Why NAD+ Doesn't Get In
- KPVKPV Structure and Physical Properties